17‐β‐estradiol reduces surface PD‐L1 expression in estrogen receptor‐positive breast cancer but not type 1 endometrial cancer cells.

Autor: Li, Hongzhuo, Gu, Wenyi, Jeffery, Penny, Chen, Chen
Předmět:
Zdroj: Clinical & Translational Medicine; Jul2023, Vol. 13 Issue 7, p1-6, 6p
Abstrakt: (E and F) The IFN- -induced PD-L1 mRNA level was diminished by E2 in the MCF-7 cells (n = 3, the exact p-value of IFN- (10 ng/ml) + 10 nM E2 vs IFN- (10 ng/ml): p = 0.0421) but not in the MDA-MB-231 cells (n = 5, the exact p-value of IFN- (10 ng/ml) + 10 nM E2 vs IFN- (10 ng/ml): p = 0.2843). Dear Editor, We report here that 17- -estradiol (E2), through ER (estrogen receptor ), inhibits IFN- -induced surface PD-L1 (programmed death-ligand 1, CD274) level in advanced ER SP + sp /HER2 SP - sp breast cancer (BC) but not in triple negative BC (TNBC) or endometrial cancer (EC). Co-exposure to BEZ235 or U0126 combined with E2 and IFN- significantly restored the proportion of the E2-downregulated IFN- -induced surface PD-L1 expressing cells in MCF-7 (Figure 4,2C), but LY294002 or other kinase inhibitors (Table S5) were not capable (Figure 4,2B,C). 17- -estradiol reduces surface PD-L1 expression in estrogen receptor-positive breast cancer but not type 1 endometrial cancer cells. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje